Replies to post #648 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

From ACG presentation on TURQUOISE-2 study:

http://acgblog.org/2014/10/14/normalization-of-liver-related-laboratory-parameters-in-hcv-genotype-1-infected-patients-with-cirrhosis-after-treatment-with-abt-450rombitasvir-dasabuvir-and-ribavirin/

In patients with cirrhosis, clearing HCV is only one goal… reversing hepatic impairment is another key, perhaps the key, endpoint…

…The improvement in standard blood tests suggests that the SVR with this Interferon-Free, All Oral regimen [ABT-450 + ABT-267 + ABT-333 ±ribavirin] improves the liver.

Good find! (Emphasis in excerpt added by me.)